Drug Database
BE

beclometasone dipropionate (Aerobec / Junik / Ventolair)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule

What is beclometasone dipropionate?

beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesAerobec, Junik, Ventolair
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

beclometasone dipropionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

beclometasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedCureus2026-07-25

Economic Burden and Cost Differences Between Branded and Generic Topical Antifungals in India.

Dt Prateek P, Dongerkery Kavitha K, Deolekar Pradnya P, Dahibhate Atharva A et al.

India's pharmaceutical market is characterized by a significant presence of both generic and branded drugs, particularly for common ailments such as superficial mycoses (SFMs), which pose a substantial public health and economic burden. Patients in tropical countries like India, which have common superficial mycoses, need prolonged treatment because of their recurrence rates after initial treatment and due to incomplete therapy. Given the high variability in drug pricing and the imperative for cost-effective healthcare, a pharmacoeconomic analysis comparing generic and branded topical antifungals in India is crucial to inform prescribing practices and optimize resource allocation. The price comparison of various topical antifungal medications from different brands was conducted by using the latest information from the "Monthly Index of Medical Specialties" August to October 2025, and 1mg online pharmacy and Jan Aushadhi website. The study calculated the total expenses for 30 mL and 30 g dosage forms, which included cream, ointment, lotion, eye drops, and shampoo products of each drug brand. We conducted a comparison between different drug brands through their cost ratio, and percentage cost variation (PCV) analysis was done, keeping generic medicines prices (retrieved from the Jan Aushadhi website) as baseline values. The data analysis showed a significant variation in the costs of different brands of topical antifungals in the Indian market. After analysis, we identified itraconazole 1% ointment to have the highest cost variation at 8335.1%, followed by clotrimazole dusting powder (4740%). Ketoconazole 2% cream, bifonazole 1% lotion, and sertaconazole shampoo showed the smallest variation at 3.29%, 3.5%, and 11.3%, respectively. When generic and branded topical antifungals were compared, the highest cost variation was seen for clotrimazole 1% cream (3431.7%), and the least variation was observed for ketoconazole 2% powder (135.4%). When combination topical antifungals were compared, the highest percentage cost variation of 1479.4% was seen for clotrimazole 1%w/w and beclomethasone dipropionate 0.025%w/w cream, and the least percentage cost variation of 38.8% was seen for terbinafine (1% w/w) + ciprofloxacin (1% w/w) + metronidazole (1% w/w) + clobetasol (0.05% w/w). The market for topical antifungal agents demonstrates substantial price variation among available products. Regulatory authorities, pharmaceutical manufacturers, and clinicians must collaborate to achieve optimal reductions in drug costs. Strict implementation of cost regulation policies, along with increased awareness among clinicians regarding the rational selection of cost-effective therapies, is essential.

PMID 42500790
Read full article →
PubMedJournal of aerosol medicine and pulmonary drug delivery2026-07-16

Toward Next-Generation Propellants: Assessing Lung Deposition of Beclometasone Dipropionate, Formoterol, and Glycopyrrolate Formulated with HFA-152a Using Functional Respiratory Imaging.

Matturro Angelo A, Monshi Tousi Navid N, Sadafi Hosein H, Cuoghi Erika E et al.

Pressurized metered-dose inhalers (pMDIs) rely on hydrofluoroalkane (HFA) propellants that have a high global warming potential (GWP). Reformulation with next-generation, low-GWP propellants, such as HFA-152a, offers a strategy to reduce climate impact; however, changes in propellant composition can affect aerosol characteristics and potentially alter lung deposition, requiring robust demonstration of therapeutic equivalence. Functional respiratory imaging, combining high-resolution computed tomography and computational fluid dynamics, was used to compare the lung deposition of a fixed triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) delivered via a pMDI formulated with either HFA-134a (Reference) or HFA-152a (Test). Ten patients with chronic obstructive pulmonary disease (GOLD stages 2-4) were retrospectively selected. Patient-specific airway geometries, a standardized inhalation profile, and formulation-specific particle size distributions and plume characteristics were applied. Deposition was quantified in the intrathoracic, central + distal, and peripheral lung regions, and the (central + distal)/peripheral ([C + D]/P) deposition ratio was evaluated. Mean intrathoracic deposition was comparable between the Reference and Test formulations, ranging from 45.95% to 46.88% of the delivered dose (DD). Deposition in the central + distal airways accounted for 12% of DD for both formulations, whereas peripheral deposition predominated, with 33.7% of DD for the Test formulation and 34.5% of DD for the Reference formulation. The (C + D)/P ratios were similar across all active components (0.35-0.37), indicating consistent preferential deposition in the peripheral/small airways. Although inter-patient variability was observed, intra-subject comparisons showed close agreement between propellants. Reformulation of the BDP/FF/GB pMDI with the low-GWP propellant HFA-152a preserved total and regional lung deposition characteristics relative to the current HFA-134a formulation. These findings support the maintenance of deposition performance while enabling a substantial reduction in environmental impact, reinforcing the potential of HFA-152a as a next-generation propellant for carbon minimal pMDI therapies.

PMID 42461266
Read full article →
PubMedLasers in medical science2026-07-16

Combined compound betamethasone and 595 nm pulsed dye laser improves hypertrophic scar and is associated with enhanced autophagy in myofibroblasts.

Sui Shijia S, Bian Shijun S, Xia Zhikuan Z, Wu Jiamin J et al.

Compound betamethasone combined with 595 nm pulsed dye laser (PDL) is widely used in the clinical management of hypertrophic scars. However, the mechanisms underlying this enhanced effect remain poorly understood. This study evaluated its therapeutic efficacy and investigated whether induction of autophagy in myofibroblasts is associated with scar improvement. A rabbit ear hypertrophic scar model was established and divided into control, compound betamethasone injection (BI), PDL, and combined (BI + PDL) groups. Scar morphology and histological changes were assessed. Autophagy was evaluated using transmission electron microscopy (TEM) and immunohistochemical detection of LC3B and p62. In vitro, hypertrophic scar-derived myofibroblasts were treated with betamethasone dipropionate (BD), PDL, or their combination (BD + PDL). Cell viability, collagen expression, and autophagic activity were analyzed using CCK-8 assays, Western blotting, MDC staining, immunofluorescence, and TEM. Chloroquine was used to assess autophagic flux. The combined BI + PDL treatment produced the most pronounced improvement in scar architecture, with reduced collagen deposition, decreased microvessel density, and increased number of apoptotic cells. Autophagy levels were significantly elevated in the combination group both in vivo and in vitro. In cultured myofibroblasts, BD + PDL markedly inhibited cell viability and reduced type I and type III collagen expression. This effect was accompanied by increased autophagosome formation, an elevated LC3II/LC3I ratio, and decreased p62 expression. Importantly, inhibition of autophagic flux with chloroquine attenuated the collagen-suppressive effect of the combined treatment. Compound betamethasone combined with 595 nm PDL significantly improves hypertrophic scars, an effect associated with enhanced autophagic activity in myofibroblasts which may partly mediate collagen degradation.

PMID 42461415
Read full article →
PubMedTopics in companion animal medicine2026-07-15

Concurrent Babesia gibsoni infection as a negative prognostics indicator of survival in dogs diagnosed with immune-mediated hemolytic anemia: A prospective cohort study.

Bandaranayaka Nishadi N, Dissanayake Anuruddhika A, Jinadasa Rasika R, Govinna Mihidum M et al.

Immune-mediated haemolytic anaemia (IMHA) is a common autoimmune disorder in dogs. Haemoparasites, particularly intracellular organisms, are well-recognized causes of secondary IMHA and are associated with poorer clinical outcomes. However, the prognostic impact of concurrent Babesia gibsoni infection in dogs with IMHA remains incompletely characterized. This study aimed to compare survival outcomes between dogs with primary IMHA and those with IMHA associated with B. gibsoni infection. Fifty-five dogs (34 purebred, 21 crossbred; age 7 months-9 years) diagnosed with IMHA, according to ACVIM guidelines, were included. Twenty-six dogs had primary IMHA (11 males, 15 females), and 29 dogs had IMHA with natural B. gibsoni infection (12 males, 17 females), confirmed by PCR. All dogs received immunosuppressive therapy consisting of prednisolone (1 mg/kg q12h PO) or dexamethasone sodium phosphate (0.2 mg/kg q24h IV). Dogs with B. gibsoni infection additionally received antibabesial treatment that included initial imidocarb dipropionate (6.6 mg/kg IM) in two weeks interval, and doxycycline up to three weeks (10 mg/kg q12h PO). Cases were followed for 60 days. Survival analysis was performed using Cox proportional hazards regression. During follow-up, 40 dogs died of IMHA and 2 from unrelated causes. In multivariable analysis, male sex (HR=2.1; 95% CI: 1.1-4.2; p=0.034), marked spherocytosis (HR=2.1; 95% CI: 1.1-4.3; p=0.032), and concurrent B. gibsoni infection (HR=2.6; 95% CI: 1.2-2.9; p=0.024) were independently associated with increased hazard of death. In conclusion, male sex, marked spherocytosis, and B. gibsoni co-infection are key independent predictors of a poor prognosis in dogs with IMHA.

PMID 42448039
Read full article →
PubMedInternational journal of chronic obstructive pulmonary disease2026-07-13

Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions.

Rogliani Paola P, Bakakos Petros P, Stolz Daiana D, Piraino Alessio A et al.

This study evaluated the real-world effectiveness and safety of extrafine single-inhaler triple therapy (SITT) with beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in chronic obstructive pulmonary disease (COPD) patients with diverse comorbidity burdens, cardiovascular (CV) history, or CV risk. A pooled analysis of six observational studies assessed outcomes in subgroups with 1-2 or ≥3 comorbidities, CV history, or CV risk. Endpoints included COPD Assessment Test (CAT) scores, exacerbation, lung function (FEV1), adherence (TAI-10), and cardiopulmonary events, evaluated at 3, 6, and 12 months. Comparisons were made with reference populations (0 comorbidities, no CV history, and no CV risk). Among 5356 patients, 2431 had 1-2 comorbidities, 1087 had ≥3, 312 had a CV history, and 117 met CV-risk criteria. CAT scores decreased significantly in all subgroups following SITT initiation. Patients with comorbidities showed smaller CAT improvements vs those without, while CV history/risk groups showed greater CAT improvements than their reference groups up to month 6. Regardless of comorbidity burden or CV history, most patients remained exacerbation-free and FEV1 improved, with no long-term differences between groups. Adherence improved as well, with patients with ≥3 comorbidities potentially showing higher adherence over the long term. Cardiopulmonary events were more frequent in higher-comorbidity groups early on but became similar over time. Patients with a CV history consistently reported more cardiopulmonary events than those without, while those with CV risk achieved similar results compared to no-risk group at any time point. This analysis provides real-world evidence supporting extrafine BDP/FF/GB SITT as an effective and safe option for COPD patients with comorbidities, including CV history or risk. These findings help address an evidence gap in vulnerable populations and support timely initiation of SITT in high-risk patients in clinical practice.

PMID 42438692
Read full article →
PubMedCurrent research in parasitology & vector-borne diseases2026-07-11

Retrospective analysis of anamnesis, clinical signs, therapy, and outcome in 342 dogs with acute Babesia canis infections.

Eisenecker Clara M CM, Moritz Andreas A, von Hohnhorst Imke M IM, Strube Christina C et al.

Babesia canis is a protozoan vector-borne pathogen causing infections in dogs. Acute B. canis infections are emerging in central and eastern Europe. Clinicopathological abnormalities include fever, thrombocytopenia, and pigmenturia. This retrospective study aimed to analyse anamnesis, stays abroad, clinicopathological abnormalities, therapy, and outcome in dogs with acute B. canis infections in Germany. Three hundred and forty-two dogs with positive piroplasmid-PCR results (B. canis identified after sequencing) and negative Anaplasma phagocytophilum-PCR results between January 2018 and December 2024 were included if data on hematocrit, platelets, and leukocytes were available. Information about anamnesis, clinical findings, therapy, and outcome was collected through questionnaires. Acute B. canis infections occurred mainly in autumn (218/342; 63.7%), followed by spring (67/342; 19.6%), winter (34/342; 9.9%), and summer (23/342; 6.7%). Most dogs tested positive in northern federal states (259/342; 75.7%), with Berlin/Brandenburg, Saxony, Saxony-Anhalt, the Saarland, the Rhine-Main area and the Ruhr area classified as high-risk areas. Lethargy (147/220; 66.8%) and fever (127/228; 55.7%) were most frequently reported. Pigmenturia was detected in 53/204 dogs (26.0%). All 164 dogs with available information on treatment received imidocarb dipropionate (median dosage 3.3 mg/kg; 1.7-6.8 mg/kg body weight). An uncomplicated course of disease was reported in most dogs (169/193, 87.6%). The mortality rate was 6.7%. Acute B. canis infections are most often uncomplicated if prompt treatment is initiated and represent a differential diagnosis in case of thrombocytopenia throughout the year, even when presented without fever and pigmenturia, especially in high-risk areas.

PMID 42433610
Read full article →

+3740 more articles available with a free account

Sign up free to view all articles →

Ask about beclometasone dipropionate